Our findings are consistent with a report of variable results for Ara‐C+ midostaurin‐treated AML cell lines and patient samples, with antagonistic effects observed frequently in wt FLT3‐expressing cells (90%) and less so in FLT3‐ITD–positive cells (60%), with little effect of the timing or sequence of the drug administration.40 Here, FLT3 is linked to acute myeloid leukemia.